Report Library
All ReportsDatamonitor Healthcare I&I: Crohn's Disease and Ulcerative Colitis Pricing & Reimbursement
March 16, 2018
Payers view spending on inflammatory bowel disease (IBD) drugs as significant, as there is a large patient base requiring expensive biologic
therapies. The market has been long dominated by the TNF-alpha inhibitors Humira and Remicade, but more recent biologic launches such
as Entyvio and Stelara have focused on novel mechanisms of action. Additionally, another alpha integrin, etrolizumab, is a further biologic of
interest to clinicians.
This Datamonitor Healthcare report contains a Pricing & Reimbursement module.
This Datamonitor Healthcare report contains a Pricing & Reimbursement module.
Indications Covered: |
Crohn's Disease
Inflammatory Bowel Disease (IBD) Ulcerative Colitis (UC) |